US equities |
MU $931.24 ▲+1.87% NVDA $217.23 ▼-1.84% SNDK $1,394.83 ▼-0.61% AMD $562.23 ▼-1.50% SPCX $148.62 ▼-2.33% INTC $95.37 ▼-2.80% AAPL $342.00 ▼-0.28% MSFT $539.44 ▲+1.08%
FinancialContent

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

59.62 +0.63 (+1.07%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
News headline image
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Earnings Outlook For Royalty Pharma ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Royalty Pharma Reports Second Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
2 Dividend Stocks Wall Street Thinks Can Rise by 50% ↗
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit. 
Via The Motley Fool
News headline image
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Third Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
News headline image
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
News headline image
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗
 
Via Benzinga
News headline image
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
News headline image
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >